Thermo Fisher to Pay $471M for Brahms | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has agreed to acquire German diagnostics firm Brahms for €330 million ($471 million) in a deal that will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.

Brahms, based in Henningsdorf, Germany, makes tests based on biomarkers for sepsis, cardiovascular, and pulmonary diseases, as well as intensive care treatments and prenatal screening products. The firm has around 400 employees in 65 countries worldwide and had 2008 annual revenues of approximately $105 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.